By an Australian General Practitioner
If you are over 30, you may have noticed something frustrating: the scales creep up even though your diet hasn’t changed, your energy dips, and the fear of a heart attack, stroke, or type 2 diabetes starts to feel very real. Maybe you have watched a parent manage diabetic kidney disease or lose independence after a stroke. Maybe perimenopause has made weight loss feel impossible. Perhaps you avoid social events because you feel self-conscious about your body. As a doctor in Australia, I hear these concerns every single day.
Semaglutide — sold in Australia as Ozempic for type 2 diabetes and Wegovy for chronic weight management — is a once-weekly injection that is changing the way we approach obesity, cardiovascular risk, and metabolic health. It is not a fad. It is not a quick fix. It is a scientifically proven medication that can help you regain control of your health after 30.
Semaglutide belongs to a class of medications called GLP-1 receptor agonists. It mimics a natural hormone called glucagon-like peptide-1, which is released after eating. This hormone sends signals to your brain that reduce appetite, slow down stomach emptying, and help you feel fuller for longer. In obesity, this biological appetite regulation is often blunted. Semaglutide restores that signal, making it easier to eat smaller portions without constant hunger or cravings.
This is not about willpower. It is about correcting a hormonal imbalance that makes sustainable weight loss extremely difficult — especially after 30, when metabolism shifts and lifestyle demands pile up.
Australian patients and researchers have been involved in global semaglutide trials, and the Therapeutic Goods Administration (TGA) has rigorously reviewed the evidence before approving it for use in Australia. The table below summarises key trials that underpin semaglutide’s benefits.
| Clinical Trial | Population | Key Finding Relevant to Australians |
|---|---|---|
| SUSTAIN-6 | Adults with type 2 diabetes and high cardiovascular risk | Reduced major cardiovascular events, including non-fatal stroke |
| STEP 1–4 | Adults with overweight or obesity | Average weight loss of approximately 15% with 2.4 mg weekly |
| SELECT | Adults with overweight/obesity and established cardiovascular disease | Reduced risk of heart attack, stroke, and cardiovascular death |
| FLOW | Adults with type 2 diabetes and chronic kidney disease | Reduced progression of diabetic kidney disease and kidney failure |
These results are not hypothetical. They come from large, randomised controlled trials with Australian participation, reflecting outcomes in people just like you — adults over 30 managing weight, blood sugar, blood pressure, and kidney function.
Stroke is one of Australia’s leading causes of death and long-term disability. If you carry extra weight, have high blood pressure, or have type 2 diabetes, your stroke risk is higher than you think. Semaglutide has been shown to reduce the risk of major cardiovascular events, including non-fatal stroke, in high-risk adults. This is not just about looking slimmer — it is about protecting your brain and your independence as you age.
Diabetic nephropathy — kidney damage caused by diabetes — is a silent threat. Many people feel fine until kidney function is already significantly reduced. The FLOW trial demonstrated that semaglutide can slow the progression of chronic kidney disease in people with type 2 diabetes, reducing the risk of kidney failure and the need for dialysis. For anyone who has watched a loved one endure dialysis three times a week, this benefit is life-changing.
Perimenopause is a perfect storm for weight gain. Oestrogen levels fluctuate, insulin resistance increases, and fat distribution shifts to the abdomen. Many women in their 40s and 50s tell me they are eating the same as always but gaining weight for the first time in their lives. Semaglutide directly addresses the hormonal drivers of appetite and insulin resistance, making it a powerful tool during perimenopause. It is not hormone replacement therapy, but it can help counteract the metabolic changes that make weight loss so difficult during this stage of life.
Weight loss is not just a physical journey — it is an emotional one. Many adults over 30 withdraw from social activities because they feel embarrassed about their weight, avoid photos, or struggle with low energy. Semaglutide can help break that cycle. As appetite reduces and weight begins to fall, many patients report improved mood, confidence, and willingness to engage socially again. However, medication works best when combined with a supportive environment. I encourage patients to involve their partner, family, or a trusted friend, and to work with a GP or dietitian. Social support amplifies semaglutide’s success.
You may have heard of tirzepatide (Mounjaro) as another new option. Both are excellent medications, but they differ in important ways.
| Feature | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Dosing | Once weekly injection | Once weekly injection |
| Average weight loss | ~15% at 2.4 mg | ~20–22% at highest dose |
| Cardiovascular outcome evidence | Strong — SUSTAIN-6 and SELECT trials | Emerging — trials ongoing |
| Kidney protection evidence | Strong — FLOW trial | Emerging |
| TGA approval in Australia | Approved for type 2 diabetes and weight management | Approved for type 2 diabetes; weight management availability varies |
While tirzepatide may produce slightly greater weight loss, semaglutide currently has the most robust evidence for stroke prevention, heart protection, and kidney protection. For many Australian adults over 30, semaglutide offers the best balance of proven long-term safety and broad metabolic protection.
I know many patients have read about a possible link between semaglutide and thyroid cancer. Let me be transparent. In animal studies, semaglutide caused thyroid C-cell tumours in rodents. However, this has not been confirmed in human trials. The concern is specifically about a rare type called medullary thyroid carcinoma. Semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or a genetic condition called MEN2. For the vast majority of Australians without this rare history, the absolute risk is extremely low, and the proven benefits for heart, brain, and kidneys far outweigh the theoretical risk. If you notice a neck lump, hoarseness, or difficulty swallowing, see your GP promptly.
If you are over 30 and tired of struggling with your weight, worried about your heart or stroke risk, or concerned about diabetes and kidney damage, semaglutide may be the tool you have been waiting for. Here is how to take action:
As a doctor, I have seen semaglutide transform lives — not just through weight loss, but through stroke prevention, kidney protection, and renewed social confidence. If you are ready to take control of your health after 30, talk to your GP today about whether semaglutide is right for you.
Disclaimer: This article is for educational purposes and does not replace individual medical advice. Always consult your doctor before starting or changing medication.
